British Lung Foundation

The Scleroderma Research Foundation (SRF) Launches Conquest Trial Platform to Address Critical Issues in Clinical Development and Enable Advances in Scleroderma Therapeutics

Retrieved on: 
Tuesday, August 1, 2023
General Health, Foundation, Health, Philanthropy, Scleroderma Research Foundation, Drug development, University, Therapy, Atmosphere, Clinical trial, Cancer, British Lung Foundation, ILD, Keck School of Medicine of USC, Research, FVC, CONQUEST, Autoimmunity, Fibrosis, Vital capacity, SRF, Imperial College London, MD, Patient, Autoimmune disease, Vascular disease, Rheumatology, Disease, Frederick, Knowledge, Ecosystem, Respiratory Medicine, British, Pharmaceutical industry, Vaccine, Medicine, Scleroderma, Sanofi

This groundbreaking effort, conceived and led by the SRF, will enroll patients across more than 130 centers in more than 22 countries. CONQUEST offers advantages to all stakeholders -- patients, physician, and drug innovators -- and provides for a seamless transition to a global Phase 3 trial, investigation of a drug’s activity in a wide range of genetic backgrounds, as well as rapid patient enrollment. By assembling a global network of high-performing centers that are dedicated to treating scleroderma, the SRF and its pharmaceutical partners expect to make enduring contributions to the scleroderma community by creating an ecosystem designed to enable success in new drug development.

Key Points: 
  • The Scleroderma Research Foundation (SRF), the nation’s largest non-profit funder of scleroderma research, today announced that Sanofi will contribute the first experimental agent to CONQUEST, a highly innovative clinical trial platform created by the SRF.
  • In the future, the CONQUEST platform will be expanded to address other manifestations of scleroderma.
  • Luke Evnin, Ph.D., Chairman of the Scleroderma Research Foundation, commented, “Our commitment to innovation in scleroderma spans basic, translational, and clinical research.
  • The initial run of CONQUEST is expected to enroll approximately 400 patients and trial initiation is targeted for Q4 2023.

​​​​​​​Less than 50% of asthma patients feel their condition is well managed, Economist Impact study finds

Retrieved on: 
Thursday, September 8, 2022
MBS, Technology, Health policy, HCPS, British Lung Foundation, Research, UNITED KINGDOM, Master of Science, Forecasting, Initiative, Royal Commission on the Future of Health Care in Canada, Solution, Disease, Paap, The Economist Group, GSK, Benchmarking, Hope, Risk, Policy, Leadership, Physician, Asthma, Time-invariant system, Chronic Respiratory Disease, Quality of life, Education, Creativity, EIU, Human, Medicine, Prevalence, Communication, Adult, Public policy, British, Degenerative disease, Gaps, Climate change, MPH, Asthma UK, Patient, GP, Pharmaceutical industry, Doctor of Philosophy, COVID-19

Less than 50% of asthma patients feel their condition is well managed, Economist Impact study finds

Key Points: 
  • Less than 50% of asthma patients feel their condition is well managed, Economist Impact study finds
    Less than 50% of asthma patients feel their condition is well managed, Economist Impact study finds
    A new study and survey by Economist Impact, with the support of GSK, shows the continuing work that needs to be done to improve quality of life for people living with asthma.
  • Poorly controlled asthma has a much higher economic burden than well managed asthma.
  • Economist Impact carried out a survey of asthma patients spanning 13 countries , looking at how they perceived their current treatment, as well as what hope they had for future care.
  • This survey highlights some of the needs and gaps along a patients asthma journey that still exist, and warrant continued efforts to improve asthma care.

Less than 50% of Asthma Patients Feel Their Condition Is Well Managed, Economist Impact Study Finds

Retrieved on: 
Tuesday, September 6, 2022
MBS, Technology, Health policy, HCPS, British Lung Foundation, Research, Master of Science, Forecasting, Initiative, Royal Commission on the Future of Health Care in Canada, Solution, Disease, Gerrit Paape, The Economist Group, GSK, Benchmarking, Hope, Risk, Policy, Leadership, Physician, Asthma, Time-invariant system, Chronic Respiratory Disease, Education, Quality of life, Creativity, EIU, Human, Medicine, Prevalence, Communication, Adult, Public policy, British, Degenerative disease, Gaps, Climate change, MPH, Asthma UK, Patient, GP, Pharmaceutical industry, Doctor of Philosophy, COVID-19

A new study and survey by Economist Impact, with the support of GSK, shows the continuing work that needs to be done to improve quality of life for people living with asthma.

Key Points: 
  • Compare that to those with controlled asthma, for whom these rates are similar to that of healthy people.
  • Economist Impact carried out a survey of asthma patients spanning 13 countries , looking at how they perceived their current treatment, as well as what hope they had for future care.
  • This survey highlights some of the needs and gaps along a patient's asthma journey that still exist, and warrant continued efforts to improve asthma care.
  • The services offered by Economist Impact previously existed within The Economist Group as separate entities, including EIU Thought Leadership, EIU Public Policy, Economist Events and SignalNoise.

Boehringer Ingelheim Canada supports PF Awareness Month with Life with PF campaign

Retrieved on: 
Monday, September 20, 2021
Degenerative disease, COPD Awareness Month, CANADA, Animal, Canadian Lung Association, Diagnosis, British Lung Foundation, Patient, Pulmonary fibrosis, Caregiver, CEO, Awareness, Disease, Life, HIV disease progression rates, Idiopathic pulmonary fibrosis, Human, PF, Quality of life, Cystic Fibrosis Foundation, Boehringer Ingelheim, Education, Medical device, Engineered wood, Fine chemical, Aluminium

BURLINGTON, ON, Sept. 20, 2021 /CNW/ - September is Pulmonary Fibrosis (PF) Awareness Month, a time to raise awareness of PF and support those who have been diagnosed with this rare lung disease.

Key Points: 
  • BURLINGTON, ON, Sept. 20, 2021 /CNW/ - September is Pulmonary Fibrosis (PF) Awareness Month, a time to raise awareness of PF and support those who have been diagnosed with this rare lung disease.
  • This year, to help patients understand the progression of this irreversible disease, and to empower them to get the care they need, Boehringer Ingelheim (Canada) Ltd. has created the Life with PF campaign.
  • "PF is a progressive disease that becomes worse over time," says Sharon Lee, Executive Director of the Canadian Pulmonary Fibrosis Foundation.
  • ABOUT BOEHRINGER INGELHEIM CANADA LTD.
    Boehringer Ingelheim is working on breakthrough therapies that improve the lives of humans and animals.

Three Lakes Foundation, Lung Foundation Australia and Centre of Research Excellence in PF join forces to create a global network for PF research

Retrieved on: 
Friday, August 6, 2021
Knowledge, Artificial intelligence, Foundation, National Health and Medical Research Council, Communication, East Lake Foundation, Degenerative disease, Pulmonary fibrosis, Bachelor of Science, COVID-19, Patient, Council for Research Excellence, Partnership, TLF, Awareness, Disease, National Health, Drug development, MBBS, Medical Research Council, Doctor of Philosophy, Diagnosis, Ecosystem, British Lung Foundation, Australian Government Information Management Office, Intelligence, VP, Center, Research, Interstitial lung disease, PF, Lung cancer, Corte, Medical device, Pharmaceutical industry, Engineered wood, Medical imaging, Uranium

Three Lakes Foundation will contribute to funding the Lung Foundation Australia and the CRE-PF, a clinically focused program with several research projects already underway.

Key Points: 
  • Three Lakes Foundation will contribute to funding the Lung Foundation Australia and the CRE-PF, a clinically focused program with several research projects already underway.
  • In addition to supporting the strategic projects, Three Lakes Foundation will work with Lung Foundation Australia and the CRE-PF to launch a global PF Coalition.
  • The Lung Foundation Australia is committed to improving the lives of individuals living with or impacted with lung disease and lung cancer.
  • Initially funded by the Australian Government's National Health and Medical Research Council, the CRE-PF builds capacity for research in PF.

COPD Foundation Journal Receives High Ranking

Retrieved on: 
Tuesday, July 6, 2021
Health, Other Science, General Health, Research, Pharmaceutical, Science, Chronic lower respiratory diseases, COPD: Journal of Chronic Obstructive Pulmonary Disease, Chronic obstructive pulmonary disease, John W. Walsh, Health, Medical specialties, British Lung Foundation, Ravi Kalhan

Last week, with receipt of its first impact factor, the peer-reviewed Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation (JCOPDF) became the highest-ranked COPD-focused journal among respiratory journals, according to Clarivates June 30, 2021, Journal Citation Report for 2020.

Key Points: 
  • Last week, with receipt of its first impact factor, the peer-reviewed Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation (JCOPDF) became the highest-ranked COPD-focused journal among respiratory journals, according to Clarivates June 30, 2021, Journal Citation Report for 2020.
  • The impact factor calculates how often articles published in the journal in 2018 and 2019 were cited in other published research articles in 2020.
  • Our journal is only seven years old, launched in 2014 by founding Editor in Chief James D. Crapo, MD, and the COPD Foundations founder, the late John W. Walsh.
  • For a non-profit foundation to publish a medical journal is no small feat, particularly in these times of large, multi-faceted, competing publishing conglomerates, said Ruth Tal-Singer, PhD, President and Chief Scientific Officer of the COPD Foundation.

American Lung Association Tackles COVID-19 through Pioneering Model of Education, Advocacy, Research

Retrieved on: 
Tuesday, March 31, 2020
Health, American Lung Association, Respiratory disease, Medicine, Lung cancer, Rho Delta Chi, British Lung Foundation

"As the nation's trusted champion of lung health, the American Lung Association is sharing the facts on COVID-19 and supporting especially those living with a lung disease and more vulnerable to the impacts of the virus," said American Lung Association President and CEO Harold Wimmer.

Key Points: 
  • "As the nation's trusted champion of lung health, the American Lung Association is sharing the facts on COVID-19 and supporting especially those living with a lung disease and more vulnerable to the impacts of the virus," said American Lung Association President and CEO Harold Wimmer.
  • The Lung Association also continues to fund lung health research, including COVID-19 research, with hopes it will translate to a potential treatment.
  • "The American Lung Association was founded by citizens faced with tuberculosis who wanted to fund research to save lives.
  • The American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy and research.

COVID-19: What Those with Lung Disease Should Know

Retrieved on: 
Thursday, March 26, 2020
Health effects of tobacco, Health, Articles, American Lung Association, Pulmonology, Chronic obstructive pulmonary disease, Lung cancer, British Lung Foundation, Respiratory Health Association of Metropolitan Chicago

The American Lung Association is supporting the health of those 36.6 million Americans living with a lung disease with science-based resources and support.

Key Points: 
  • The American Lung Association is supporting the health of those 36.6 million Americans living with a lung disease with science-based resources and support.
  • It's important for those with lung disease to use their best practices in managing their disease, including for example COPD, which is already a high-risk disease for readmissions to the hospital."
  • For journalists seeking to schedule an interview with an expert about COVID-19, lung disease and lung health, contact Stephanie Goldina at the American Lung Association at 312-801-7629 or [email protected] .
  • The American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy and research.

Lung Cancer Research Foundation Unveils Redesign Of Its Website

Retrieved on: 
Wednesday, January 22, 2020
Health, Lung cancer, Epidemiology, Cancer, Cancer research, Neoplasms, Lung Cancer Alliance, British Lung Foundation

NEW YORK, Jan. 22, 2020 /PRNewswire/ -- The Lung Cancer Research Foundation (LCRF), the largest lung cancer focused foundation in the US supporting lung cancer research, has unveiled its newly revamped website, lcrf.org .The recently updated website has a fresh visual design, offers easy navigation and is mobile optimized.

Key Points: 
  • NEW YORK, Jan. 22, 2020 /PRNewswire/ -- The Lung Cancer Research Foundation (LCRF), the largest lung cancer focused foundation in the US supporting lung cancer research, has unveiled its newly revamped website, lcrf.org .The recently updated website has a fresh visual design, offers easy navigation and is mobile optimized.
  • The Lung Cancer Research Foundation (LCRF) is the leading nonprofit organization focused on funding innovative, high-reward research with the potential to extend survival and improve quality of life for people with lung cancer.
  • LCRF's mission is to improve lung cancer outcomes by funding research for the prevention, diagnosis, treatment and cure of lung cancer.
  • To date, LCRF has funded 370 research grants, totaling nearly $34 million, the highest amount provided by a nonprofit organization dedicated to funding lung cancer research.In addition to funding lung cancer research, the organization offers awareness and educational programs and brings the lung cancer community together through Free to Breathe Walks and other events nationwide.

Victor Dahdaleh Visits Cambridge to See Progress in Mesothelioma Research

Retrieved on: 
Thursday, December 19, 2019
Health, Cancer, Asbestos, Neoplasms, Mesothelioma, RTT, BLF, British Lung Foundation

From that original donation, the BLF and the mesothelioma research community has leveraged nearly 25 million of additional funding into mesothelioma research from a wide variety of sources.

Key Points: 
  • From that original donation, the BLF and the mesothelioma research community has leveraged nearly 25 million of additional funding into mesothelioma research from a wide variety of sources.
  • Recently, Canadian Philanthropist, Victor Dahdaleh visited Cambridge, with British Lung Foundation Chief Executive, Dr Penny Woods, to receive updates on progress with key strands of the research programming: MesobanK (a mesothelioma biobank); the BLF-Royal Papworth Hospital mesothelioma training fellowships; and the mesothelioma organoid project.
  • On conclusion of the visit, Victor Dahdaleh commented:
    "It is intensely gratifying to see how the original donation that the Foundation made has helped to generate such widespread support and interest into mesothelioma research.
  • For further information on The Victor Dahdaleh Foundation contact Matthew Moth at Madano on t: +44 (0)207-593-4000 or e: [email protected]